Chimeric Animal Immune Tolerance Breakthrough

Publication ID: 24-11856927_0010_PTD

Published: October 26, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Chimeric Animal Immune Tolerance Breakthrough,” Published Technical Disclosure No. 24-11856927_0010_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856927_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,927.

Background and Problem Solved

The original patent relates to finding and treating inflammation after birth in chimeric animals. However, it is limited to treating immune responses and inflammation after they occur. The present invention addresses the need for a more proactive and personalized approach to inducing immune tolerance, treating inflammation, and modeling human diseases in chimeric animals.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the field by proactively inducing immune tolerance, using precision-guided immunomodulatory therapy, and providing real-time monitoring of immune responses. These advancements are non-obvious and go beyond the original patent's focus on treating immune responses and inflammation after they occur.

Alternative Embodiments and Variations

Alternative embodiments of the invention could include using different cell types, modifying the cell selection and expansion modules, or integrating the system with other disease modeling platforms. Variations of the invention could also include using the system for modeling different human diseases or developing new therapeutic strategies.

Potential Commercial Applications and Market

The invention has significant commercial potential in the fields of regenerative medicine, disease research, and personalized medicine. The target market includes pharmaceutical companies, biotech firms, and research institutions seeking to develop novel therapeutics and disease models.

CPC Classifications

Section	Class	Group
A	A01	A01K67/0271
A	A61	A61K31/573
A	A61	A61P37/06
A	A01	A01K2217/05
A	A01	A01K2217/075
A	A01	A01K2227/105
A	A01	A01K2267/035
C	C12	C12N15/09

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Veterinary biotechnology and immunological research, specifically focused on chimeric animal models, stem cell manipulation, and immune system modulation

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in veterinary medicine, immunology, or biotechnology, experienced in stem cell techniques, animal model development, and immunological research methodologies

Obviousness Rationale

A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about managing immune responses in chimeric animals. The disclosed techniques leverage known immunological principles and standard research methodologies for enhancing and monitoring immune tolerance. The systematic approach to cell selection, expansion, and immune response monitoring represents incremental improvements that would be obvious to a skilled researcher in the field.

Obvious Combinations & Variations

Source Patent Element

Method for obtaining an adult individual from a chimeric animal fetus with no substantial inflammation

PTD Variation

Cell selection module for identifying and isolating low immunogenicity cells

Obviousness Reasoning

Predictable refinement of existing immune management techniques using standard cell isolation technologies known in biotechnology

Source Patent Element

Administering anti-inflammatory or immunosuppressive agents before immune response occurrence

PTD Variation

Precision-guided immunomodulatory therapy tailored to specific inflammation profiles

Obviousness Reasoning

Logical progression of immunological intervention strategies using known personalized medicine approaches

Source Patent Element

Chimeric animal method focusing on post-birth immune response management

PTD Variation

Real-time monitoring device for detecting immune response biomarkers

Obviousness Reasoning

Obvious technological enhancement using standard biomarker detection and data analysis techniques

Source Patent Element

Immunodeficient individual in chimeric animal model

PTD Variation

Personalized chimeric animal model generated using patient-specific cells

Obviousness Reasoning

Predictable application of existing personalized medicine principles to chimeric animal research

Source Patent Element

Xenogeneic or allogeneic chimeric animal fetus methodology

PTD Variation

Blastocyst-complemented chimeric animal with humanized immune system

Obviousness Reasoning

Logical extension of existing chimeric animal research techniques using known stem cell and genetic modification approaches

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856927 and the disclosed technical variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The systematic approach to immune tolerance, cell selection, and personalized chimeric animal modeling represents predictable variations that would be readily conceived by a skilled researcher in the field of veterinary biotechnology and immunological research.

Original Patent Information

Patent Number	US 11,856,927
Title	Finding and treatment of inflammation after birth in chimeric animal
Assignee(s)	The University of Tokyo